"2" . "CZ - \u010Cesk\u00E1 republika" . "Kmenov\u00E9 bu\u0148ky a karcinom ovaria : Charakteristika, v\u00FDznam a potenci\u00E1ln\u00ED aplikace v klinick\u00E9 praxi"@cs . . . . . "RIV/00064165:_____/13:10188737!RIV14-MZ0-00064165" . "1210-7832" . . . "Ovarian cancer is the most malignant and the second most common gynecological cancer which encompasses a heterogeneous group of tumors with a different etiology. Extra-ovarian tissues may play a role in the development of ovarian cancer, despite this issue is still debated. This disease is associated with a strong chemoresistance and tendency to recurrence, and asymptomatic behaviour at early stages. Effective screening markers have not been established yet. Cancer stem cells have been postulated to play a role within tumor formation and by the establishment of chemotherapy-resistant population of malignant cells after the surgery and application of chemotherapy. These cells are multipotent cells capable of un-limited divisions and have potential to induce tumorigenesis in immune-suppressed mice. Their detailed characterization is still an open issue, however there have been identified several markers associated with ovarian cancer stem cells. The major markers of ovarian cancer stem cells identified so far are CD133, ALDH, CD44, CD117, CD24 and EpCAM. Their occurrence in primary tumors may be associated with patients' prognosis; however there are insufficient data for definite conclusions. Dynamic processes of carcinogenesis result also in changes of cancer stem cells phenotypes based on the microenvironmental changes within the tumor. The markers may thus be acquired, or lost, as it has been proven experimentally. As regards the possibility to use targeted, specific therapy approaches, there are some promising studies, suggesting this may be a method of potential treatment. Further characterization and functional studies of cancer stem cells will be necessary for the elucidation of carcinogenesis, chemoresistance and metastases formation-associated processes. The most recent results on ovarian cancer stem cells research are presented in this paper."@en . "EpCAM; CD117; CD24; CD44; ALDH; CD133; treatment; diagnostics; ovarian cancer; Cancer stem cells"@en . . "3"^^ . . "Kmenov\u00E9 bu\u0148ky a karcinom ovaria : Charakteristika, v\u00FDznam a potenci\u00E1ln\u00ED aplikace v klinick\u00E9 praxi" . "\u010Cesk\u00E1 gynekologie" . "[C3950CE13AC0]" . "RIV/00064165:_____/13:10188737" . . . "2"^^ . "I" . "Kmenov\u00E9 bu\u0148ky a karcinom ovaria : Charakteristika, v\u00FDznam a potenci\u00E1ln\u00ED aplikace v klinick\u00E9 praxi"@cs . "Jand\u00E1kov\u00E1, Eva" . "Z\u00E1vesk\u00FD, Lud\u011Bk" . "Nejzhoubn\u011Bj\u0161\u00ED a druh\u00E9 nejb\u011B\u017En\u011Bj\u0161\u00ED gynekologick\u00E9 n\u00E1dorov\u00E9 onemocn\u011Bn\u00ED - karcinom ovaria - je heterogenn\u00ED skupinou n\u00E1dor\u016F s rozd\u00EDlnou etiologi\u00ED. P\u0159esto\u017Ee dosud nen\u00ED jednotn\u00FD n\u00E1zor na zp\u016Fsob jeho vzniku, ukazuje se, \u017Ee roli mohou hr\u00E1t extra-ovari\u00E1ln\u00ED tk\u00E1n\u011B. Onemocn\u011Bn\u00EDje prov\u00E1zeno silnou chemorezistenc\u00ED a tendenc\u00ED k recidiv\u011B, sou\u010Dasn\u011B s \u010Dasto asymptomatick\u00FDm pr\u016Fb\u011Bhem onemocn\u011Bn\u00ED v \u010Dasn\u00FDch f\u00E1z\u00EDch. Efektivn\u00ED screeningov\u00E9 markery dosud nebyly objeveny. P\u0159i vzniku n\u00E1doru i p\u0159i ustaven\u00ED chemorezistentn\u00ED populace n\u00E1dorov\u00FDch bun\u011Bk v poopera\u010Dn\u00EDm obdob\u00ED a po aplikaci chemoterapie hraj\u00ED podle nejnov\u011Bj\u0161\u00EDch v\u00FDzkum\u016F roli n\u00E1dorov\u00E9 kmenov\u00E9 bu\u0148ky. N\u00E1dorov\u00E9 kmenov\u00E9 bu\u0148ky jsou multipotentn\u00ED bu\u0148ky s neomezenou schopnost\u00ED se d\u011Blit, kter\u00E9 maj\u00ED schopnost experiment\u00E1ln\u011B indukovat vznik n\u00E1dor\u016F u imunodeficientn\u00EDch my\u0161\u00ED. Detailn\u00ED charakteristika t\u011Bchto bun\u011Bk je st\u00E1le otev\u0159enou z\u00E1le\u017Eitost\u00ED, ale ji\u017E byly identifikov\u00E1ny jejich typick\u00E9 markery. Dosud identifikovan\u00E9 hlavn\u00ED markery t\u011Bchto bun\u011Bk jsou CD133, ALDH, CD44, CD117, CD24 a EpCAM. Zv\u00FD\u0161en\u00FD v\u00FDskyt ur\u010Dit\u00FDch populac\u00ED t\u011Bchto bun\u011Bk u prim\u00E1rn\u00EDch n\u00E1dor\u016F m\u016F\u017Ee b\u00FDt asociov\u00E1n s progn\u00F3zou v\u00FDvoje nemoci, ale jednozna\u010Dn\u00E1 interpretace neexistuje vzhledem ke st\u00E1le nedostate\u010Dn\u00E9mu mno\u017Estv\u00ED dat. Dynamika karcinogeneze a asociovan\u00FDch proces\u016F vede tak\u00E9 k tomu, \u017Ee kmenov\u00E9 bu\u0148ky mohou m\u011Bnit sv\u00E9 fenotypy v z\u00E1vislosti na m\u011Bn\u00EDc\u00EDch se podm\u00EDnk\u00E1ch prost\u0159ed\u00ED. Kmenov\u00E9 bu\u0148ky jsou tedy schopny uveden\u00E9 markery z\u00EDskat nebo ztratit, jak bylo prok\u00E1z\u00E1no experiment\u00E1ln\u011B. Zat\u00EDm omezen\u00E9 mo\u017Enosti tak\u00E9 existuj\u00ED v souvislosti s c\u00EDlenou specifickou terapi\u00ED proti kmenov\u00FDm bu\u0148k\u00E1m, a\u010Dkoli n\u011Bkter\u00E9 p\u0159edb\u011B\u017En\u00E9 v\u00FDsledky nazna\u010Duj\u00ED, \u017Ee by to mohla b\u00FDt vhodn\u00E1 cesta. Dal\u0161\u00ED charakteriza\u010Dn\u00ED a funk\u010Dn\u00ED studie n\u00E1dorov\u00FDch kmenov\u00FDch bun\u011Bk budou nezbytn\u00E9 pro pochopen\u00ED proces\u016F spojen\u00FDch s karcinogenez\u00ED, chemorezistenc\u00ED a tvorbou metast\u00E1z. V \u010Dl\u00E1nku p\u0159in\u00E1\u0161\u00EDme p\u0159ehled nejnov\u011Bj\u0161\u00EDch poznatk\u016F o roli n\u00E1dorov\u00FDch kmenov\u00FDch bun\u011Bk u karcinomu ovaria." . . "Kohoutov\u00E1, Milada" . . . "6"^^ . "Nejzhoubn\u011Bj\u0161\u00ED a druh\u00E9 nejb\u011B\u017En\u011Bj\u0161\u00ED gynekologick\u00E9 n\u00E1dorov\u00E9 onemocn\u011Bn\u00ED - karcinom ovaria - je heterogenn\u00ED skupinou n\u00E1dor\u016F s rozd\u00EDlnou etiologi\u00ED. P\u0159esto\u017Ee dosud nen\u00ED jednotn\u00FD n\u00E1zor na zp\u016Fsob jeho vzniku, ukazuje se, \u017Ee roli mohou hr\u00E1t extra-ovari\u00E1ln\u00ED tk\u00E1n\u011B. Onemocn\u011Bn\u00EDje prov\u00E1zeno silnou chemorezistenc\u00ED a tendenc\u00ED k recidiv\u011B, sou\u010Dasn\u011B s \u010Dasto asymptomatick\u00FDm pr\u016Fb\u011Bhem onemocn\u011Bn\u00ED v \u010Dasn\u00FDch f\u00E1z\u00EDch. Efektivn\u00ED screeningov\u00E9 markery dosud nebyly objeveny. P\u0159i vzniku n\u00E1doru i p\u0159i ustaven\u00ED chemorezistentn\u00ED populace n\u00E1dorov\u00FDch bun\u011Bk v poopera\u010Dn\u00EDm obdob\u00ED a po aplikaci chemoterapie hraj\u00ED podle nejnov\u011Bj\u0161\u00EDch v\u00FDzkum\u016F roli n\u00E1dorov\u00E9 kmenov\u00E9 bu\u0148ky. N\u00E1dorov\u00E9 kmenov\u00E9 bu\u0148ky jsou multipotentn\u00ED bu\u0148ky s neomezenou schopnost\u00ED se d\u011Blit, kter\u00E9 maj\u00ED schopnost experiment\u00E1ln\u011B indukovat vznik n\u00E1dor\u016F u imunodeficientn\u00EDch my\u0161\u00ED. Detailn\u00ED charakteristika t\u011Bchto bun\u011Bk je st\u00E1le otev\u0159enou z\u00E1le\u017Eitost\u00ED, ale ji\u017E byly identifikov\u00E1ny jejich typick\u00E9 markery. Dosud identifikovan\u00E9 hlavn\u00ED markery t\u011Bchto bun\u011Bk jsou CD133, ALDH, CD44, CD117, CD24 a EpCAM. Zv\u00FD\u0161en\u00FD v\u00FDskyt ur\u010Dit\u00FDch populac\u00ED t\u011Bchto bun\u011Bk u prim\u00E1rn\u00EDch n\u00E1dor\u016F m\u016F\u017Ee b\u00FDt asociov\u00E1n s progn\u00F3zou v\u00FDvoje nemoci, ale jednozna\u010Dn\u00E1 interpretace neexistuje vzhledem ke st\u00E1le nedostate\u010Dn\u00E9mu mno\u017Estv\u00ED dat. Dynamika karcinogeneze a asociovan\u00FDch proces\u016F vede tak\u00E9 k tomu, \u017Ee kmenov\u00E9 bu\u0148ky mohou m\u011Bnit sv\u00E9 fenotypy v z\u00E1vislosti na m\u011Bn\u00EDc\u00EDch se podm\u00EDnk\u00E1ch prost\u0159ed\u00ED. Kmenov\u00E9 bu\u0148ky jsou tedy schopny uveden\u00E9 markery z\u00EDskat nebo ztratit, jak bylo prok\u00E1z\u00E1no experiment\u00E1ln\u011B. Zat\u00EDm omezen\u00E9 mo\u017Enosti tak\u00E9 existuj\u00ED v souvislosti s c\u00EDlenou specifickou terapi\u00ED proti kmenov\u00FDm bu\u0148k\u00E1m, a\u010Dkoli n\u011Bkter\u00E9 p\u0159edb\u011B\u017En\u00E9 v\u00FDsledky nazna\u010Duj\u00ED, \u017Ee by to mohla b\u00FDt vhodn\u00E1 cesta. Dal\u0161\u00ED charakteriza\u010Dn\u00ED a funk\u010Dn\u00ED studie n\u00E1dorov\u00FDch kmenov\u00FDch bun\u011Bk budou nezbytn\u00E9 pro pochopen\u00ED proces\u016F spojen\u00FDch s karcinogenez\u00ED, chemorezistenc\u00ED a tvorbou metast\u00E1z. V \u010Dl\u00E1nku p\u0159in\u00E1\u0161\u00EDme p\u0159ehled nejnov\u011Bj\u0161\u00EDch poznatk\u016F o roli n\u00E1dorov\u00FDch kmenov\u00FDch bun\u011Bk u karcinomu ovaria."@cs . "78" . "http://www.prolekare.cz/linkout/40541" . "Cancer stem cells and ovarian cancer : Characteristics, importance and potential applications in clinical practice"@en . . . "82773" . . . . . . . . "Cancer stem cells and ovarian cancer : Characteristics, importance and potential applications in clinical practice"@en . "Kmenov\u00E9 bu\u0148ky a karcinom ovaria : Charakteristika, v\u00FDznam a potenci\u00E1ln\u00ED aplikace v klinick\u00E9 praxi" . .